#India #Chicago #PRMT5 Inhibitor #Lupin Limited #LNP7457

Lupin Limited to Present Groundbreaking Phase 1 Data at ASCO 2025

Lupin Limited, a leading global pharmaceutical company, is gearing up to showcase remarkable findings from its Phase 1a clinical trial of LNP7457, a promising PRMT5 inhibitor. The presentation will take place at the prestigious American Society of Clinical Oncology (ASCO) annual meeting, held in Chicago, Illinois, from May 30 to June 3, 2025.

Key Presentation Details:

• - Title: A Phase 1 Dose Escalation Study of LNP7457 (PRMT5 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors
• - Date and Time: June 2, 2025, from 1:30 PM to 4:30 PM CDT
• - Location: Hall A - Posters and Exhibits | McCormick Place, Chicago, IL
• - Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
• - Poster Board Number: 422

Study Highlights:

The main findings from this pivotal study reveal that LNP7457 exhibits a favorable safety profile and is generally well tolerated among patients suffering from advanced and metastatic solid tumors. Moreover, the drug showcases a promising pharmacokinetics and pharmacodynamics (PK/PD) profile, with no adverse food interactions affecting its pharmacokinetics. These findings are crucial as they lay the foundation for future therapeutic applications, particularly in treating cancers that currently present significant challenges and unmet medical needs.

The maximum tolerated dose has been established through comprehensive evaluations of safety, efficacy, and PK/PD data, aligning with earlier preclinical insights and the established safety portfolios of PRMT5 inhibitors.

Vinita Gupta, CEO of Lupin, expressed excitement regarding these initial results, emphasizing the company’s commitment to innovation and developing advanced treatment options for patients dealing with difficult cancers. "We are enthusiastic about sharing these promising results and are dedicated to enhancing patient health outcomes through groundbreaking science," Gupta stated during the announcement.

Unique Position of LNP7457:

Current evidence suggests that LNP7457 is distinct in its category, standing out among other therapeutic options available for oncological treatment. The company is eagerly anticipating the next step, which involves further exploration of LNP7457’s efficacy in a subsequent Phase 1b trial scheduled to take place in India. This trial is aimed at assessing the treatment’s effectiveness for other cancer types that face critical unmet medical needs.

About Lupin Limited:

Lupin Limited, headquartered in Mumbai, India, is recognized as a prominent player in the global pharmaceutical landscape. With a diverse product portfolio distributed across over 100 markets, Lupin specializes in creating innovative pharmaceutical solutions, such as branded and generic formulations, biotechnology products, and active pharmaceutical ingredients.

The pharmaceutical giant has made significant inroads in various therapeutic domains, including respiratory, cardiovascular, anti-diabetic, anti-infective, and women's health. Equipped with 15 state-of-the-art manufacturing facilities and 7 dedicated research centers worldwide, Lupin employs over 23,000 professionals, all committed to the company’s mission of improving healthcare outcomes globally. The company's subsidiaries further enable its growth in diagnostics, digital health, and manufacturing solutions.

As the ASCO annual meeting draws near, the medical community eagerly anticipates the insights that will emerge from Lupin's presentation, which promises to pave the way for new strides in cancer treatment methodologies, demonstrating the efficacy and safety of this groundbreaking PRMT5 inhibitor, LNP7457.